Superior persistence of ustekinumab compared to anti-TNF in vedolizumab-experienced inflammatory bowel diseases patients: a real-world cohort study
Abstract Background/Aims The increasing use of biologic therapies for moderate to severe inflammatory bowel disease (IBD) highlights the importance of optimal treatment sequencing, particularly after vedolizumab (VDZ) exposure. Studies comparing the effectiveness of ustekinumab (UST) and antitumor n...
Saved in:
| Main Authors: | Horng-Yih Chiu, Chia-Jung Kuo, Ming-Wei Lai, Ren-Chin Wu, Chien-Ming Chen, Cheng-Tang Chiu, Yu-Bin Pan, Cheng-Hsun Chiu, Puo-Hsien Le |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-024-03577-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Patients with Ulcerative Colitis: A Real-World Retrospective Study
by: Kei Nomura, et al.
Published: (2024-09-01) -
The Effects of the Biological Agents Infliximab, Vedolizumab, and Ustekinumab on Intestinal Anastomosis: An Experimental Study in Rats
by: Alexandra Menni, et al.
Published: (2025-04-01) -
Comparative efficacy and safety of vedolizumab and antitumor necrosis factor alfa in patients with inflammatory bowel diseases: A meta‑analysis
by: Li Yafang, et al.
Published: (2025-03-01) -
The Use of Tissue Concentrations of Biological and Small-Molecule Therapies in Clinical Studies of Inflammatory Bowel Diseases
by: Ahmed B. Bayoumy, et al.
Published: (2024-11-01) -
Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study
by: Abdulhamid Alhadab, et al.
Published: (2025-03-01)